
Expres²ion and Intravacc enter collaboration agreement

Hørsholm, Denmark / Bilthoven, the Netherlands, December 11, 2017 – Today, Expres²ion Biotechnologies ApS (“Expres²ion”) and Intravacc (the Institute for Translational Vaccinology), announce the signing of a collaboration agreement. This agreement strengthens Expres²ion’s ability to service customers and partners across the full value chain of vaccine development and expands the commercial opportunities for both organisations. Under the agreement, Intravacc will serve as a preferred GMP (Good Manufacturing Practice) partner for Expres²ion. The agreement contains no financial exchange between Expres²ion and Intravacc. However, it expands the commercial opportunities in the vaccine field for both organisations.

Memorandum of Understanding

Expres²ion, a fully owned subsidiary of Expres²ion Biotech Holding AB, and Intravacc, an experienced vaccine R&D institute, have signed a Memorandum of Understanding (MoU). The MoU enables Expres²ion to service customers and collaboration partners across the full value chain of development of vaccines, from discovery up till GMP production and clinical trials. Under the agreement, Intravacc will serve as a preferred GMP partner for Expres²ion. Serving as a reference for expanded customer outreach, the MoU contains no financial exchange between Expres²ion and Intravacc. However, it expands the commercial opportunities in the vaccine field for both organisations.

Expres²ion CEO Dr. Steen Klysner comments

“We are very satisfied to expand Expres²ion’s capabilities into the manufacturing of vaccines through the establishment of a preferred partnership with Intravacc. This strategic alliance increases Expres²ion’s service offerings and continues our repositioning into a one-stop solution provider for vaccine developing SMEs and Pharma companies.”

Intravacc CEO Thijs Veerman Msc comments

“We are proud to serve as a preferred GMP partner for Expres²ion and its clientele. Intravacc offers one-stop solutions for GMP production and clinical development and has a strong track record in the technology transfer of vaccine products and knowhow to our partners. Our experience with the development and successful technology transfer of vaccines such as Haemophilus influenzae b and Sabin inactivated Polio vaccine to vaccine manufacturers has paved the way for a fast and product oriented route to market.”

About Intravacc

Intravacc, based in Bilthoven, the Netherlands, is an established R&D organisation with more than 100 years’ experience in optimisation of vaccines, vaccine processes and vaccine technologies. Intravacc has state-of-the-art production facilities and its aim is to substantially

reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide. More information at www.intravacc.nl.

For further information about Intravacc, please contact:

Thijs Veerman Msc, CEO

Telephone: +31 30 7920445

E-mail: thijs.veerman@intravacc.nl

Certified Adviser

Sedermersa Fondskommission is appointed as Certified Adviser for ExpreS²ion.

For further information about ExpreS²ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: sk@expres2ionbio.com

This press release contains information that ExpreS²ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on December 11, 2017.

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion's unique proprietary platform technology, ExpreS², is designed to enable accelerated, cost effective development and robust production of complex proteins for new vaccines and diagnostics. Since founded in 2010, more than 250 proteins involved in e.g. malaria and Zika were produced in collaborations with research institutions and companies with a superior efficiency and success rate. ExpreS²ion also develops competitive virus-like-particle based vaccines through its joint venture AdaptVac, which was founded in 2017.